Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 7/20 | 0.58 |
| ▸ | CES1 | P23141 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | TERT | O14746 | 3/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.51 |
| ▸ | PPARG | P37231 | 3/20 | 0.51 |
| ▸ | PPARD | Q03181 | 3/20 | 0.51 |
| ▸ | PPARA | Q07869 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | BLM | P54132 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | FABP4 | P15090 | 2/20 | 0.51 |
| ▸ | GMNN | O75496 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29110836 | 0.91 | FAAH (0.50) | FAAHCES1CYP1A2KMT2AMEN1 | |
| SCHEMBL28044207 | 0.85 | FAAH (0.71) | FAAHCES1CYP1A2CYP2C19KMT2A | |
| SCHEMBL28818411 | 0.83 | FAAH (0.52) | FAAHCES1CYP1A2CYP2C19KMT2A | |
| Hydrochloric Acid SCHEMBL29006654 | 0.82 | FAAH (0.67) | FAAHCES1CYP1A2CYP2C19KMT2A | |
| SCHEMBL9354962 | 0.81 | FAAH (0.65) | FAAHCES1CYP1A2CYP2C19KMT2A | |
| SCHEMBL8935063 | 0.81 | FAAH (0.65) | FAAHCES1CYP1A2CYP2C19KMT2A | |
| SCHEMBL29072795 | 0.80 | FAAH (0.63) | FAAHCES1CYP1A2CYP2C19KMT2A | |
| SCHEMBL723655 | 0.80 | FAAH (0.63) | FAAHCES1CYP1A2CYP2C19KMT2A | |
| SCHEMBL9330785 | 0.79 | FAAH (0.67) | FAAHCES1CYP1A2CYP2C19KMT2A | |
| SCHEMBL31280143 | 0.79 | FAAH (0.67) | FAAHCES1CYP1A2CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507374-B1 | NOVEL THERAPEUTIC RNA INTERFERENCE TECHNOLOGY TARGETED TO THE PDX-1 ONCOGENE IN PDX-1 EXPRESSING NEUROENDOCRINE TUMORS | STRIKE BIO INC (US) | 2016-12-07 | — | — | EP | disclosed |
| US-9133459-B2 | Therapeutic RNA interference technology targeted to the PDX-1 oncogene in PDX-1 expressing neuroendocrine tumors | STRIKE BIO, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-8906874-B2 | Bi-functional shRNA targeting Stathmin 1 and uses thereof | GRADALIS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20130295160-A1 | ANTAGONISTS OF MIR-196A | STRIKE BIO, INC. | 2013-11-07 | — | — | US | disclosed |
| WO-2013151981-A1 | EWING'S SARCOMA BIFUNCTIONAL SHRNA DESIGN | GRADALIS, INC. (US) | 2013-10-10 | — | — | WO | disclosed |
| US-20130266639-A1 | METHODS FOR TREATING TRIPLE NEGATIVE BREAST CANCER USING BIFUNCTIONAL SRC 3 shRNA | STRIKE BIO, INC. | 2013-10-10 | — | — | US | disclosed |
| US-20130259925-A1 | METHODS AND COMPOSITIONS TO TREAT CANCER USING BIFUNCTIONAL SRC 3 shRNA | BAYLOR COLLEGE OF MEDICINE (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130259927-A1 | Ewing's Sarcoma Bifunctional shRNA Design | GRADALIS, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| WO-2013148824-A1 | METHODS AND COMPOSITIONS TO TREAT CANCER USING BIFUNCTIONAL SRC-3 shRNA | GRADALIS, INC. (US) | 2013-10-03 | — | — | WO | disclosed |
| US-20130084331-A1 | Novel Therapeutic RNA Interference Technology Targeted to the PDX-1 Oncogene in PDX-1 Expressing Neuroendocrine Tumors | BAYLOR COLLEGE OF MEDICINE (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130064881-A1 | COMPOSITIONS AND METHODS FOR TREATING PROSTATE CANCER | GRADALIS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-8361983-B2 | Therapeutic RNA interference technology targeted to the PDX-1 oncogene in PDX-1 expressing neuroendocrine tumors | GRADALIS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2507374-A2 | NOVEL THERAPEUTIC RNA INTERFERENCE TECHNOLOGY TARGETED TO THE PDX-1 ONCOGENE IN PDX-1 EXPRESSING NEUROENDOCRINE TUMORS | Gradalis, Inc. (US) | 2012-10-10 | — | — | EP | disclosed |
| US-20120251617-A1 | BI-FUNCTIONAL SHRNA TARGETING STATHMIN 1 AND USES THEREOF | GRADALIS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20110117183-A1 | Novel Therapeutic RNA Interference Technology Targeted to the PDX-1 Oncogene in PDX-1 Expressing Neuroendocrine Tumors | GRADALIS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2011053660-A2 | NOVEL THERAPEUTIC RNA INTERFERENCE TECHNOLOGY TARGETED TO THE PDX-1 ONCOGENE IN PDX-1 EXPRESSING NEUROENDOCRINE TUMORS | GRADALIS, INC. (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2009062104-A2 | ABERRANT EXPRESSION OF ZINC TRANSPORTER ZIP4 (SLC39A4) SIGNIFICANTLY CONTRIBUTES TO HUMAN PANCREATIC CANCER PATHOGENESIS AND PROGRESSION | BAYLOR COLLEGE OF MEDICINE (US) | 2009-05-14 | — | — | WO | disclosed |